These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17161858)

  • 1. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse.
    Coughlin M; Lou G; Martinez O; Masterman SK; Olsen OA; Moksa AA; Farzan M; Babcook JS; Prabhakar BS
    Virology; 2007 Apr; 361(1):93-102. PubMed ID: 17161858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
    van den Brink EN; Ter Meulen J; Cox F; Jongeneelen MA; Thijsse A; Throsby M; Marissen WE; Rood PM; Bakker AB; Gelderblom HR; Martina BE; Osterhaus AD; Preiser W; Doerr HW; de Kruif J; Goudsmit J
    J Virol; 2005 Feb; 79(3):1635-44. PubMed ID: 15650189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
    He Y; Li J; Heck S; Lustigman S; Jiang S
    J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
    Tripp RA; Haynes LM; Moore D; Anderson B; Tamin A; Harcourt BH; Jones LP; Yilla M; Babcock GJ; Greenough T; Ambrosino DM; Alvarez R; Callaway J; Cavitt S; Kamrud K; Alterson H; Smith J; Harcourt JL; Miao C; Razdan R; Comer JA; Rollin PE; Ksiazek TG; Sanchez A; Rota PA; Bellini WJ; Anderson LJ
    J Virol Methods; 2005 Sep; 128(1-2):21-8. PubMed ID: 15885812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
    Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
    J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
    Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
    J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
    Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
    Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.
    Rockx B; Donaldson E; Frieman M; Sheahan T; Corti D; Lanzavecchia A; Baric RS
    J Infect Dis; 2010 Mar; 201(6):946-55. PubMed ID: 20144042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
    Coughlin MM; Prabhakar BS
    Rev Med Virol; 2012 Jan; 22(1):2-17. PubMed ID: 21905149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
    He Y; Li J; Du L; Yan X; Hu G; Zhou Y; Jiang S
    Vaccine; 2006 Jun; 24(26):5498-508. PubMed ID: 16725238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
    Berry JD; Hay K; Rini JM; Yu M; Wang L; Plummer FA; Corbett CR; Andonov A
    MAbs; 2010; 2(1):53-66. PubMed ID: 20168090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
    He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
    J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus.
    Lip KM; Shen S; Yang X; Keng CT; Zhang A; Oh HL; Li ZH; Hwang LA; Chou CF; Fielding BC; Tan TH; Mayrhofer J; Falkner FG; Fu J; Lim SG; Hong W; Tan YJ
    J Virol; 2006 Jan; 80(2):941-50. PubMed ID: 16378996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.
    Elshabrawy HA; Coughlin MM; Baker SC; Prabhakar BS
    PLoS One; 2012; 7(11):e50366. PubMed ID: 23185609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening.
    Zhang X; Wang J; Wen K; Mou Z; Zou L; Che X; Ni B; Wu Y
    Viral Immunol; 2009 Dec; 22(6):407-15. PubMed ID: 19951177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody.
    Bian C; Zhang X; Cai X; Zhang L; Chen Z; Zha Y; Xu Y; Xu K; Lu W; Yan L; Yuan J; Feng J; Hao P; Wang Q; Zhao G; Liu G; Zhu X; Shen H; Zheng B; Shen B; Sun B
    Virology; 2009 Jan; 383(1):39-46. PubMed ID: 18986662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV.
    Mitsuki YY; Ohnishi K; Takagi H; Oshima M; Yamamoto T; Mizukoshi F; Terahara K; Kobayashi K; Yamamoto N; Yamaoka S; Tsunetsugu-Yokota Y
    Microbes Infect; 2008 Jul; 10(8):908-15. PubMed ID: 18606245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.